Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
Condition: Hypercholesterolemia · Sponsor: Federico II University
About this study
Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.
This description comes directly from the study's public registry record.
Talk to the study team
Pasquale Perrone Filardi, MD · +390817462224 · fpperron@unina.it
Always discuss trial participation with your own doctor first.
Locations (27)
| Ospedali dell'Ovest Vicentino | Arzignano, Italy | Recruiting |
| University of Bari Aldo Moro | Bari, Italy | Recruiting |
| University of Campania Luigi Vanvitelli | Caserta, Italy | Recruiting |
| University Magna Graecia of Catanzaro | Catanzaro, Italy | Recruiting |
| Presidio Ospedaliero Maria SS Addolorata | Eboli, Italy | Recruiting |
| Policlinico Riuniti Foggia | Foggia, Italy | Recruiting |
| Università degli Studi di Genova | Genova, Italy | Recruiting |
| Ospedale di Lecce | Lecce, Italy | Recruiting |
| Università degli Studi di Messina | Messina, Italy | Recruiting |
| Policlinico di Milano Ospedale Maggiore - Fondazione IRCCS Ca' Granda | Milan, Italy | Recruiting |
| ASST Grande Ospedale Metropolitano Niguarda | Milan, Italy | Recruiting |
| AORN dei Colli - Ospedale monaldi | Naples, Italy | Recruiting |
+ 15 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05430828